Table 4 Cox regression analyses of changes of clinical parameters in CHB patients after 1 year of entecavir treatment for prediction of HBeAg seroconversion at year 5.

  Sex (female vs. male)^a

0.972 (0.390–2.422)

0.952

  Age^a

0.996 (0.957–1.038)

0.855

HBV genotype (non-C vs. C)^a

0.710 (0.338–1.494)

0.367

  Metavir score (F2-F3/F0-F1)^a

0.551 (0.165–1.834)

0.331

  FIB-4

1.282 (0.711–2.310)

0.409

  ALT

1.002 (0.999–1.005)

0.128

  AST

1.004 (0.999–1.101)

0.152

  TB

1.037 (0.971–1.107)

0.274

  ALB

0.861 (0.721–1.027)

0.096

  WBC

0.900 (0.649–1.249)

0.529

  HBsAg

1.503 (0.850–2.652)

0.160

HBeAg

1.005 (1.000–1.010)

0.057

HBV DNA^a

0.620 (0.459–0.838)

0.002

  Virologic response (Y/N)^b

3.580 (1.074–11.941)

0.038

  VWF: Ag

0.997 (0.947–1.042)

0.116

  ADAMTS13: AC

1.115 (1.052–1.181)

0.006

  ALB

1.044 (0.914–1.192)

0.527

  HBeAg

1.001 (0.996–1.006)

0.704

  HBV DNA^a

0.723 (0.514–0.976)

0.043

  Virologic response (Y/N)

1.079 (0.180–6.471)

0.933

  ADAMTS13: AC

1.109 (1.021–1.185)

0.015